Welcome to the healthcare professionals section
In this section, you will find information on RenehaVis™ and its use in knee osteoarthitis (OA).
We have included RenehaVis™ prescribing information, clinical reference, a video demonstrating the mechanism of action of RenehaVis™ and other useful information.
If you require further assistance, please contact us.
A clinical study was conducted studying the effects of RenehaVis™, a high molecular weight HA, a low molecular weight HA and placebo. This double blind, placebo controlled study in Canada showed that patients administered with RenehaVis™ had less pain scores when walking and at rest compared to the other three arms in the study in a shorter period of time.
RenehaVis patients had the lowest pain score after the 2nd injection and this was maintained for up to 16 weeks.
An innovative product for knee OA, RenehaVis™ is the only product in the world that contains 2 Hyaluronic Acids in 1 syringe for a sequential injection.
Chamber 1 contains: Low molecular weight HA – High concentration
Chamber 2 contains: High molecular weight HA – Low concentration
RenehaVis™ offers to both patients and doctors the DMC concept: Dual Molecular weight and Concentration concept in 1 syringe.
All viscosupplementation try to help knee OA patients regain a healthy physiological state of the knee. Low molecular weight HA is known to be able to act as a lubricant in the knee whereas high molecular HA is known for its ability to absorb shocks experienced by the knee.
Low molecular weight HA has 2 other functions:
Diffuse through the cartilage to protect the chondrocytes (note: a molecule which help create endogenous HA and proteoglycans) which are commonly destroyed in knee OA patients. This is often terms as the CAGING EFFECT.
Diffuse to the synoviocytes at the synovial membrane to activate them. This results in the generation of endogenous HA. This action is known as the MECHANOSENSITIVE EFFECT.
This is why RenehaVis™ has a concentration of low molecular weight HA – to achieve these 3 criteria needed in an OA knee.
The high molecular weight HA is at a lower concentration as it only has 1 function (shock absorber) and it only has to maintain this function whilst the low molecular weight HA acts.
RenehaVis™ can be re-administered to patients after 6 months.
RenehaVis™ is administered via an intra-articular injection into the knee synovial capsule. Care should always be taken to ensure that entry into the synovial capsule is obtained. There are various techniques to do an intra-articular injection. It depends greatly on what you are most comfortable with.
There were no serious adverse events during the clinical study. Non-serious adverse events included pain and local swelling at the injection site (21%), erythema at the injection site (12%), and stiffness in the index knee (7%) amongst all groups.